Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today reported business updates and financial results for the first quarter ended March 31, 2025.

Read more at globenewswire.com